Zhejiang Yatai Pharmaceutical Co., Ltd. (SHE:002370)
China · Delayed Price · Currency is CNY 5.37
-0.20 (-3.59%)
Sep 10, 2026, 3:04 PM CST
SHE:002370 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 327.85 | 321.39 | 402.22 | 416.92 | 372.86 | 312.77 |
Other Revenue | 0.74 | 1.75 | 2.96 | 3.72 | 0.58 | 2.37 |
| 328.58 | 323.14 | 405.17 | 420.64 | 373.44 | 315.13 | |
Revenue Growth | -2.01% | -20.25% | -3.68% | 12.64% | 18.50% | -38.80% |
Cost of Revenue | 222.93 | 228.36 | 284.42 | 288.54 | 247.23 | 210.24 |
Gross Profit | 105.65 | 94.78 | 120.75 | 132.1 | 126.22 | 104.89 |
Selling, General & Admin | 93.65 | 105.01 | 110.51 | 137.6 | 129.66 | 209.45 |
Research & Development | 14.94 | 15.47 | 14.64 | 21.79 | 26.14 | 28.62 |
Other Operating Expenses | 0.22 | 2.84 | 4.03 | 6.14 | 5.38 | 5.31 |
Operating Expenses | 108.82 | 123.56 | 129.76 | 165.11 | 162.21 | 236.02 |
Operating Income | -3.17 | -28.78 | -9.01 | -33.01 | -35.99 | -131.13 |
Interest Expense | -0.06 | -34.7 | -30.59 | -47.46 | -52.31 | -56.87 |
Interest & Investment Income | 5.81 | 158.98 | 65.12 | 16.08 | 11.78 | 15.99 |
Currency Exchange Gain (Loss) | - | -0 | -0.35 | - | - | - |
Other Non Operating Income (Expenses) | 0.69 | 1.04 | 0.55 | -1.07 | -0.97 | -0.03 |
EBT Excluding Unusual Items | 3.27 | 96.54 | 25.72 | -65.45 | -77.49 | -172.04 |
Gain (Loss) on Sale of Investments | -7.24 | 0.83 | 1.64 | 1.78 | -17.32 | -14.95 |
Gain (Loss) on Sale of Assets | -0.06 | -0.06 | -0.01 | 0.4 | 0.04 | 8.61 |
Asset Writedown | -13.98 | -10.96 | -0.16 | -4.71 | -40.27 | -22.06 |
Legal Settlements | -1.25 | -1.27 | -4.93 | 51.9 | -8.66 | -21.11 |
Other Unusual Items | 9.36 | 11.35 | 12.23 | 4.53 | 8.39 | -2.6 |
Pretax Income | -9.9 | 96.43 | 34.49 | -11.56 | -135.32 | -224.16 |
Income Tax Expense | -0.52 | 0.12 | 0.25 | 0.31 | -2.63 | 4.12 |
Earnings From Continuing Operations | -9.38 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Net Income to Company | -9.38 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Minority Interest in Earnings | 0.08 | - | - | - | - | - |
Net Income | -9.3 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Net Income to Common | -9.3 | 96.31 | 34.24 | -11.88 | -132.69 | -228.28 |
Net Income Growth | - | 181.28% | - | - | - | - |
Shares Outstanding (Basic) | 728 | 741 | 685 | 594 | 531 | 531 |
Shares Outstanding (Diluted) | 728 | 741 | 685 | 594 | 531 | 531 |
Shares Change | -7.45% | 8.18% | 15.32% | 11.89% | -0.02% | -2.68% |
EPS (Basic) | -0.01 | 0.13 | 0.05 | -0.02 | -0.25 | -0.43 |
EPS (Diluted) | -0.01 | 0.13 | 0.05 | -0.02 | -0.25 | -0.43 |
EPS Growth | - | 160.00% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -77.16 | 23.84 | 14.44 | 7.19 | -9.06 | -19.62 |
Free Cash Flow Per Share | -0.11 | 0.03 | 0.02 | 0.01 | -0.02 | -0.04 |
Gross Margin | 32.15% | 29.33% | 29.80% | 31.40% | 33.80% | 33.28% |
Operating Margin | -0.96% | -8.91% | -2.22% | -7.85% | -9.64% | -41.61% |
Profit Margin | -2.83% | 29.80% | 8.45% | -2.82% | -35.53% | -72.44% |
Free Cash Flow Margin | -23.48% | 7.38% | 3.56% | 1.71% | -2.43% | -6.23% |
EBITDA | 23.52 | -1.72 | 27.92 | 5.49 | 4.43 | -88.54 |
EBITDA Margin | 7.16% | -0.53% | 6.89% | 1.31% | 1.19% | -28.10% |
D&A For EBITDA | 26.69 | 27.06 | 36.93 | 38.51 | 40.42 | 42.59 |
EBIT | -3.17 | -28.78 | -9.01 | -33.01 | -35.99 | -131.13 |
EBIT Margin | -0.96% | -8.91% | -2.22% | -7.85% | -9.64% | -41.61% |
Effective Tax Rate | - | 0.13% | 0.71% | - | - | - |
Revenue as Reported | 171.06 | 323.14 | 405.17 | 420.64 | 373.44 | 315.13 |